GO:0005518 collagen binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005518 collagen binding is a molecular function describing the selective, non-covalent interaction of a protein with collagen, a glycine- and proline-rich fibrous protein of the extracellular matrix.
• Collagen binding is mediated by conserved structural modules such as the integrin I domain, the glycoprotein VI immunoglobulin-like domains, and the DDR discoidin domain.
• Key collagen-binding protein families include integrins, DDR1/DDR2, GPVI, von Willebrand factor, HSP47, and SPARC.
• Collagen binding underlies platelet adhesion and activation, cell-matrix adhesion, collagen fibril assembly, and tissue remodelling.
• Dysregulated collagen binding contributes to thrombosis, fibrosis, cancer progression, and envenomation-related coagulopathy.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of collagen-binding proteins in human disease.
Description
Collagen binding (GO:0005518) is a molecular function defined as the selective interaction of a protein with collagen, a group of fibrous proteins of very high tensile strength that form the main component of connective tissue in animals. Collagen is highly enriched in glycine and proline, occurring predominantly as 3-hydroxyproline, and its triple-helical architecture presents repeating binding motifs that are recognised by dedicated receptor modules. Because collagen is the most abundant protein in the human body, proteins that bind it are central to cell adhesion, platelet activation, matrix assembly, and tissue homeostasis. Researchers study collagen binding to understand how cells sense and remodel the extracellular matrix, and to identify therapeutic targets in thrombosis, fibrosis, and cancer. The function is experimentally defined by direct binding assays, structural biology, and genetic perturbation of the interacting proteins.
collagen binding At A Glance
| GO ID | GO:0005518 |
|---|---|
| GO term | collagen binding |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Binding to collagen, a group of fibrous proteins of very high tensile strength that form the main component of connective tissue in animals; collagen is highly enriched in glycine and proline, occurring predominantly as 3-hydroxyproline. |
| Major function | Mediates cell adhesion, platelet activation, matrix assembly, and tissue remodelling through selective recognition of collagen triple-helical and fibrillar motifs. |
| Representative domains | Integrin I domain, immunoglobulin-like domains, discoidin domain, VWF A domains, HSP47 serpin fold. |
| Cellular context | Extracellular matrix, plasma membrane, platelet surface, endoplasmic reticulum (for chaperones). |
| Related diseases | Thrombosis, fibrosis, cancer, osteogenesis imperfecta, envenomation coagulopathy. |
What Is GO:0005518?
In the Gene Ontology, GO:0005518 collagen binding describes the function of a protein that selectively and non-covalently interacts with collagen. Collagen is a fibrous structural protein family characterised by a triple-helical domain, high glycine content (some regions are 33% glycine), and abundant proline, predominantly as 3-hydroxyproline (about 20%). Collagen-binding proteins recognise specific sequence motifs or higher-order fibrillar features, often through conserved domains such as the integrin I domain, immunoglobulin-like domains, or discoidin domains. This function is distinct from collagen synthesis or collagen cross-linking; it specifically denotes the binding event itself.
Why Is collagen binding Important in Cell Biology?
Collagen binding is fundamental to how cells interact with the most abundant protein in the extracellular matrix. It controls platelet adhesion and thrombus formation, regulates cell proliferation and migration through integrin and DDR signalling, and ensures correct collagen fibril assembly through chaperones such as HSP47. Because collagen-binding proteins are exposed on cell surfaces and in plasma, they are attractive pharmaceutical targets for antithrombotic and antifibrotic therapies. Mutations or dysregulation of collagen-binding proteins are linked to bleeding disorders, thrombosis, fibrosis, and cancer progression.
• Collagen binding mediates platelet adhesion and activation via GPVI and integrin α2β1, making it central to haemostasis and thrombosis.
• Integrin collagen receptors regulate cell adhesion, migration, proliferation, and survival in development and tissue repair.
• DDR1 and DDR2 are collagen-binding receptor tyrosine kinases that control matrix remodelling and are implicated in fibrosis and cancer.
• HSP47 is a collagen-specific chaperone whose binding is required for correct procollagen folding and secretion.
• Von Willebrand factor binding to sub-endothelial collagen initiates platelet plug formation under high shear.
• Collagen-binding integrins are validated pharmaceutical targets for antithrombotic and anti-inflammatory drugs.
• Cryptic collagen-binding sites can be exposed by fibril deformation, altering cell-matrix communication in disease.
• Collagen binding is exploited by bacterial and snake venom proteins to disrupt host haemostasis.
• Altered collagen binding contributes to tumour stroma stiffening and cancer cell invasion.
• CRISPR models of collagen-binding genes enable causal testing of these roles in human cells and animals.
Molecular Mechanism of collagen binding
Recognition of collagen triple-helical motifs
In simple terms: Collagen-binding proteins have specialised pockets that fit the repeating shape of collagen.
Collagen presents a repetitive Gly-X-Y triple-helical surface that is recognised by conserved receptor domains. The integrin I domain coordinates a metal ion that engages collagen glutamate residues, while GPVI uses immunoglobulin-like domains to bind collagen with low micromolar affinity. DDR receptors bind collagen through their discoidin domain in a tyrosine kinase-dependent manner. These interactions are sequence-specific and depend on the collagen primary structure, including the high glycine and 3-hydroxyproline content.
Fibrillar versus monomeric collagen binding
In simple terms: Some proteins bind single collagen molecules, while others only bind assembled collagen fibres.
Collagen-binding proteins discriminate between monomeric and fibrillar collagen. GPVI binds collagen fibres but not monomers, and its binding is enhanced by collagen glycation and cross-linking. Cryptic binding sites within the collagen fibril can become accessible upon mechanical deformation, revealing that fibril architecture regulates binding. DDR receptors require native triple-helical collagen and bind fibrils with slow kinetics.
Metal-ion and cofactor dependence
In simple terms: Many collagen-binding proteins need metal ions to hold collagen correctly.
Integrin I domains contain a metal-ion-dependent adhesion site (MIDAS) that coordinates Mg2+ or Mn2+ to bind collagen glutamate. The von Willebrand factor A1 domain also uses a metal-independent but conformationally regulated site to bind collagen. HSP47 binding to collagen is pH- and calcium-dependent within the endoplasmic reticulum.
Regulation by conformational change and signalling
In simple terms: Cells can switch collagen binding on or off by changing protein shape or signalling.
Integrin affinity for collagen is regulated by inside-out signalling that switches the receptor from a low- to high-affinity conformation. DDR1 and DDR2 are activated by collagen binding, leading to autophosphorylation and downstream signalling. GPVI collagen binding triggers platelet activation through the FcRγ-chain and Syk pathway. These regulatory mechanisms allow dynamic control of adhesion and signalling.
Collagen chaperone binding in the secretory pathway
In simple terms: Inside cells, chaperones bind collagen to help it fold correctly.
HSP47 is a collagen-specific molecular chaperone that binds newly synthesised procollagen in the endoplasmic reticulum and prevents premature fibril formation. Its binding site on native collagen has been mapped, and inhibitors of HSP47-collagen binding are being developed for fibrosis. This intracellular collagen binding is essential for collagen quality control and secretion.
Key Genes Involved in GO:0005518 collagen binding
The following genes encode proteins with experimentally validated collagen-binding activity, representing the major families that mediate this function.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ITGA1 | Integrin α1 subunit; forms α1β1 collagen receptor | Cell adhesion, fibrosis, cancer |
| ITGA2 | Integrin α2 subunit; forms α2β1 collagen receptor | Platelet adhesion, thrombosis |
| ITGB1 | Integrin β1 subunit; partners with α1/α2/α10/α11 | Broad collagen-binding integrin signalling |
| ITGA10 | Integrin α10 subunit; collagen receptor in cartilage | Chondrocyte biology, osteoarthritis |
| ITGA11 | Integrin α11 subunit; collagen receptor in fibroblasts | Fibrosis, tumour stroma |
| GP6 | Glycoprotein VI; platelet collagen receptor | Platelet activation, antithrombotic target |
| DDR1 | Discoidin domain receptor 1; collagen-activated RTK | Fibrosis, cancer, inflammation |
| DDR2 | Discoidin domain receptor 2; collagen-activated RTK | Skeletal development, fibrosis |
| VWF | Von Willebrand factor; binds sub-endothelial collagen | Haemostasis, thrombosis, envenomation |
| HSP47 (SERPINH1) | Collagen-specific chaperone | Collagen folding, fibrosis, osteogenesis imperfecta |
| SPARC | Matricellular protein that binds collagen | Matrix assembly, cancer |
| COL1A1 | Type I collagen α1 chain; ligand for collagen-binding proteins | Bone, fibrosis, cancer |
| COL1A2 | Type I collagen α2 chain; ligand | Connective tissue disorders |
| COL2A1 | Type II collagen α1 chain; ligand in cartilage | Chondrodysplasias |
| COL3A1 | Type III collagen α1 chain; ligand in vessels | Vascular Ehlers-Danlos |
| COL4A1 | Type IV collagen α1 chain; basement membrane ligand | Angiopathy, cancer |
| COL6A1 | Type VI collagen α1 chain; microfibrillar ligand | Muscular dystrophy |
How Is collagen binding Regulated?
Collagen binding is regulated at multiple levels. Integrin affinity is controlled by inside-out signalling that induces conformational changes in the I domain, modulating ligand binding. DDR1 and DDR2 are regulated by collagen-induced dimerisation and autophosphorylation, which control downstream signalling. GPVI collagen binding is modulated by receptor clustering and by the plasma membrane environment. Extracellularly, collagen fibril structure and exposure of cryptic sites regulate accessibility to binding proteins. Intracellularly, HSP47 binding to procollagen is regulated by pH and calcium in the endoplasmic reticulum. These layers of regulation ensure that collagen binding is context-dependent and reversible.
collagen binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GP6 | Thrombosis, platelet dysfunction | Platelet-specific knockout; point mutation of collagen-binding site |
| ITGA2 | Bleeding disorders, antithrombotic target | Knockout in megakaryocytes; knock-in of patient variants |
| DDR1 | Fibrosis, cancer | Conditional knockout in fibroblasts; kinase-dead knock-in |
| HSP47 (SERPINH1) | Osteogenesis imperfecta, fibrosis | Knockout in collagen-secreting cells; overexpression of mutant |
| VWF | Von Willebrand disease, thrombosis | Knock-in of collagen-binding domain mutations |
Thrombosis and haemostasis
Collagen binding by platelet receptors GPVI and integrin α2β1 is essential for platelet adhesion and activation at sites of vascular injury. Excessive collagen binding can promote pathological thrombus formation, and von Willebrand factor binding to sub-endothelial collagen facilitates thrombotic events in Bothrops lanceolatus envenomation. Collagen-binding integrins are therefore pharmaceutical targets for antithrombotic therapy.
Fibrosis and cancer
DDR1 and DDR2 are collagen-binding receptor tyrosine kinases that drive fibrotic remodelling and tumour progression. Integrin α11β1 and α1β1 on fibroblasts and cancer cells promote collagen deposition and matrix stiffening, supporting tumour growth and metastasis. HSP47 binding to collagen is required for excessive collagen secretion in fibrosis, and HSP47 inhibitors are under development.
Connective tissue and skeletal disorders
Mutations in collagen genes or in collagen-binding chaperones such as HSP47 cause connective tissue disorders including osteogenesis imperfecta and related skeletal dysplasias. Defective collagen binding by integrins or DDRs can impair bone and cartilage development.
From collagen binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a collagen receptor impair platelet adhesion? | CRISPR knockout of GP6 or ITGA2 in megakaryocytic cell lines or primary platelets |
| Does a point mutation in the integrin I domain abolish collagen binding? | CRISPR point mutation (e.g., MIDAS motif) in ITGA2 followed by adhesion assays |
| Does a disease-associated variant alter collagen binding affinity? | Knock-in of the patient variant into the endogenous locus; surface plasmon resonance |
| Where does a collagen-binding protein localise in tissues? | Endogenous knock-in of a fluorescent tag (e.g., GFP) into the gene of interest |
| Does overexpression of a collagen-binding protein drive fibrosis? | Doxycycline-inducible overexpression in fibroblasts or organoids |
| Which genes regulate collagen binding in a genome-wide screen? | CRISPR knockout library screening with collagen-coated surfaces |
How to Study the collagen binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Solid-phase binding ELISA | Direct binding of protein to immobilised collagen | Validate integrin or GPVI collagen binding |
| Surface plasmon resonance | Kinetics and affinity (KD) of collagen binding | Characterise DDR or integrin interactions |
| X-ray crystallography | Atomic structure of collagen-binding interface | Guide inhibitor design |
| Platelet aggregation assay | Functional platelet response to collagen | Test GPVI and integrin inhibitors |
| Cell adhesion assay | Adhesion of cells to collagen matrix | Evaluate integrin function |
| CRISPR knockout screen | Genes required for collagen binding | Discover novel regulators |
| Immunofluorescence | Localisation of collagen-binding proteins in tissues | Assess expression in fibrosis or cancer |
| Co-immunoprecipitation | Physical interaction between collagen and binding protein | Confirm binding in cell lysates |
Solid-phase collagen binding assays
Recombinant or purified collagen-binding proteins are incubated with immobilised collagen, and bound protein is detected by ELISA or radiolabelling. This method quantifies affinity and specificity and is widely used to validate integrin and GPVI binding.
Surface plasmon resonance (SPR) and biolayer interferometry
SPR measures real-time association and dissociation kinetics of collagen-binding proteins with immobilised collagen, providing equilibrium dissociation constants (KD). It has been used to characterise GPVI-collagen and DDR-collagen interactions.
Structural biology (crystallography and cryo-EM)
X-ray crystallography and cryo-electron microscopy reveal the atomic details of collagen-binding interfaces, such as the GPVI immunoglobulin-like domains bound to collagen. These structures guide inhibitor design.
Cell adhesion and platelet aggregation assays
Cells expressing collagen-binding receptors are allowed to adhere to collagen-coated surfaces, and adhesion is quantified. Platelet aggregation in response to collagen measures GPVI and integrin function.
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens can identify genes that regulate collagen binding, using collagen-coated plates and cell survival or fluorescence-based readouts.
How CRISPR Can Be Used to Study GO:0005518 collagen binding
Knockout
CRISPR knockout of collagen-binding genes such as ITGA2, GP6, or DDR1 eliminates the protein and allows assessment of loss-of-function phenotypes in adhesion, signalling, and disease models. Knockout cell lines are essential for validating specificity of collagen-binding inhibitors.
Point Mutation
CRISPR point mutation can introduce specific amino acid substitutions in collagen-binding domains, such as the integrin MIDAS motif or GPVI collagen-binding residues, to dissect the contribution of individual residues to binding affinity and downstream signalling.
Knock-in
Knock-in of disease-associated variants or fluorescent tags into endogenous collagen-binding genes enables physiological expression and real-time imaging of protein localisation and dynamics. This approach is valuable for modelling patient-specific mutations.
Overexpression
CRISPR-mediated overexpression or inducible expression of collagen-binding proteins can model gain-of-function states observed in fibrosis and cancer, and can be used to test whether increased collagen binding drives pathological matrix remodelling.
How EDITGENE Supports collagen binding Research
Researchers studying collagen binding-related genes often need to determine whether a candidate gene is causally involved in adhesion, signalling, or disease. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for collagen binding research.
Frequently Asked Questions About collagen binding
What is collagen binding (GO:0005518)?
Collagen binding is a molecular function defined as the selective, non-covalent interaction of a protein with collagen, a fibrous extracellular matrix protein rich in glycine and proline.
What genes are involved in collagen binding?
Key genes include ITGA1, ITGA2, ITGB1, GP6, DDR1, DDR2, VWF, and HSP47 (SERPINH1), which encode proteins that directly bind collagen.
What proteins bind to collagen?
Integrins, glycoprotein VI, discoidin domain receptors, von Willebrand factor, HSP47, and SPARC are well-characterised collagen-binding proteins.
How is collagen binding measured?
Common methods include solid-phase binding assays, surface plasmon resonance, cell adhesion assays, and platelet aggregation.
What diseases are associated with abnormal collagen binding?
Thrombosis, fibrosis, cancer, osteogenesis imperfecta, and von Willebrand disease are linked to altered collagen binding.
What is the role of GPVI in collagen binding?
GPVI is a platelet receptor that binds collagen fibres and triggers platelet activation through the FcRγ-chain and Syk pathway.
How do integrins bind collagen?
Integrin I domains coordinate a metal ion to engage collagen glutamate residues, and affinity is regulated by inside-out signalling.
What is the function of HSP47 in collagen binding?
HSP47 is a collagen-specific chaperone that binds procollagen in the endoplasmic reticulum to ensure correct folding and secretion.
Can CRISPR be used to study collagen binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of collagen-binding genes in human cells.
What are the therapeutic targets in collagen binding?
Collagen-binding integrins and GPVI are pursued as antithrombotic targets, while DDRs and HSP47 are targeted for fibrosis and cancer.
Conclusion
Collagen binding (GO:0005518) is a central molecular function that governs how cells and platelets interact with the most abundant extracellular matrix protein. Through conserved domains in integrins, GPVI, DDRs, VWF, and HSP47, collagen binding controls adhesion, signalling, matrix assembly, and tissue remodelling. Dysregulation of these interactions contributes to thrombosis, fibrosis, cancer, and connective tissue disorders, making collagen-binding proteins important therapeutic targets. CRISPR-based models provide a powerful approach to dissect the causal roles of these proteins in human disease.
References
- 1. Gullberg DE et al.. 2002. Collagen-binding I domain integrins--what do they do?. Prog Histochem Cytochem 37(1):3-54 PMID: 11876085
- 2. Eble JA. 2005. Collagen-binding integrins as pharmaceutical targets.. Curr Pharm Des 11(7):867-80 PMID: 15777240
- 3. Feitsma LJ et al.. 2022. Structural insights into collagen binding by platelet receptor glycoprotein VI.. Blood 139(20):3087-3098 PMID: 35245360
- 4. Orgel JPRO et al.. 2019. A structural prospective for collagen receptors such as DDR and their binding of the collagen fibril.. Biochim Biophys Acta Mol Cell Res 1866(11):118478 PMID: 31004686
- 5. Hoop CL et al.. 2017. Revealing Accessibility of Cryptic Protein Binding Sites within the Functional Collagen Fibril.. Biomolecules 7(4) PMID: 29104255
- 6. Barczyk M et al.. 2010. Integrins.. Cell Tissue Res 339(1):269-80 PMID: 19693543
- 7. Pierre-Louis O et al.. 2023. Increased Binding of von Willebrand Factor to Sub-Endothelial Collagen May Facilitate Thrombotic Events Complicating Bothrops lanceolatus Envenomation in Humans.. Toxins (Basel) 15(7) PMID: 37505710
- 8. Cai H et al.. 2021. Identification of HSP47 Binding Site on Native Collagen and Its Implications for the Development of HSP47 Inhibitors.. Biomolecules 11(7) PMID: 34356607
